Oral versus Parenteral anticoagulation in the prophylaxis and therapeutic management of thromboembolic disease in hospitalised patients with confirmed COVID-19 disease

Dhiraj Kumar0 个研究点目标入组 230 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Participants were enrolled after RT PCR-evidence of COVID-19 infection or radiological evidence of COVID-19 associated mild or moderate infection requiring hospitalisation.
•2. Ages 25 to 75 years.
•3. If mild infection (uncomplicated URTI without evidence of breathlessness or hypoxia [SpO2 >94% as defined by local guidelines), to be included if CHADSVASc2 score is >=2 if female, >=1 if male; D-dimer levels >500 ng/mL or have previous history of malignancy, deep vein thrombosis (DVT), systemic embolism or ischaemic events.
•4. All patients with moderate infection (features of pneumonia with dyspnoea, hypoxia [SpO2 90-94%], respiratory rate >23/minute as defined by local guidelines) to be included regardless of CHADSVASC score and D-D-dimer levels.
•5. Documented informed consent

•Severe disease (pneumonia with SpO2 <90% or respiratory rate >30/minute or severe respiratory distress) or critical illness (signs of shock, sepsis, multi-organ failure.
•Chronic liver disease ((e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or ALAT > 3 x ULN.
•Chronic kidney disease (eGFR <30 mL/min/1.73m2).
•History of intracranial bleeding in the last 3 months.
•Bleeding diathesis, active peptic ulcer disease.
•Pregnancy or first postpartum week.
•Refractory hypertension (SBP >180 mmHg).
•Any other contraindication listed in the local labelling of enoxaparin and rivaroxaban

发起方

Dhiraj Kumar